Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology’s Annual Scientific Session

Rhea-AI Summary

Picard Medical (NYSE: PMI) will present early preclinical data for its next‑generation Emperor Total Artificial Heart at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28–30, 2026.

The poster, titled THE EMPEROR TOTAL ARTIFICIAL HEART, is scheduled for March 29, 2026 at 11:00 a.m., and SynCardia will also staff exhibit booth #2554 to discuss the fully implantable, autoregulating electromechanical heart platform and related development plans.

News Market Reaction – PMI

+2.68%

1 alert

+2.68% News Effect

+$2M Valuation Impact

$86M Market Cap

0.2x Rel. Volume

On the day this news was published, PMI gained 2.68%, reflecting a moderate positive market reaction. This price movement added approximately $2M to the company's valuation, bringing the market cap to $86M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 28–30, 2026 Poster session time: 11:00 a.m.–12:00 p.m. Booth number: Booth #2554 +5 more

8 metrics

Conference dates March 28–30, 2026 ACC.26 Annual Scientific Session & Expo

Poster session time 11:00 a.m.–12:00 p.m. Abstract poster on March 29, 2026

Booth number Booth #2554 SynCardia exhibit location at ACC.26

Conference year ACC.26 American College of Cardiology 2026 meeting

Current share price $1.12 Pre-news market context for PMI

52-week high $13.68 Upper end of 52-week trading range

52-week low $0.15 Lower end of 52-week trading range

Market cap $85,493,364 Equity value before ACC.26 news

Market Reality Check

Price: $0.9900 Vol: Volume 81,147 is below th...

low vol

$0.9900 Last Close

Volume Volume 81,147 is below the 20-day average of 217,945, suggesting limited pre-news positioning. low

Technical Price at $1.12 is trading below the 200-day MA of $2.78, reflecting a longer-term downtrend.

Peers on Argus

Within Medical Devices peers, moves are mixed: CTKB +5.13%, LAB +1.31%, KIDS -0....

1 Up

Within Medical Devices peers, moves are mixed: CTKB +5.13%, LAB +1.31%, KIDS -0.72%, while AVMR and ZIMV are flat. PMI’s -3.45% move contrasts with this mixed backdrop, indicating stock-specific dynamics around its artificial heart updates.

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 17	Clinical milestone case	Positive	-10.2%	Reported 1,636 days of SynCardia Total Artificial Heart support before transplant.
Mar 13	Media visibility	Positive	-4.7%	Announced FOX Business BTV segment featuring SynCardia Total Artificial Heart and Emperor program.
Mar 12	Business update webcast	Positive	-4.7%	Scheduled Annual Business Update to review 2025 results and Emperor platform progress.
Mar 02	Conference data presentations	Positive	+0.0%	Showcased new clinical and preclinical data for SynCardia and fully implantable Emperor system.
Feb 26	Training conference event	Positive	-0.9%	Participated in THT 2026 hands-on training day for SynCardia Total Artificial Heart use.

Pattern Detected

Recent clinically oriented and promotional announcements have often coincided with flat-to-negative price reactions, despite positive operational tone.

Recent Company History

Over the last month, Picard Medical has repeatedly highlighted progress and visibility for its SynCardia Total Artificial Heart and the fully implantable Emperor platform. Events include a hands-on training day on Feb 26, new data at THT 2026 on Mar 2, and an upcoming business update on Mar 25. Despite largely positive clinical and visibility themes, prior news on Mar 12–17 saw -4.65% to -10.24% moves, indicating weak market enthusiasm for similar updates.

Market Pulse Summary

This announcement highlights Picard Medical’s continued effort to showcase its fully implantable Emp...

Analysis

This announcement highlights Picard Medical’s continued effort to showcase its fully implantable Emperor Total Artificial Heart at ACC.26, emphasizing early engineering and preclinical data and reinforcing SynCardia’s position in advanced heart failure therapy. In the past month, similar conference and visibility events around SynCardia and Emperor were frequent. Investors may track clinical progression beyond preclinical data, upcoming business updates on March 25, 2026, and how these initiatives build on the company’s established total artificial heart platform.

Key Terms

total artificial heart, autoregulating, preclinical, hemodynamic performance, +4 more

8 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

autoregulating medical

"a fully implantable, autoregulating artificial heart platform"

A system or device described as autoregulating adjusts its own behavior automatically to keep performance within set limits without continuous outside control. For investors, autoregulation can mean lower operating costs and less need for oversight but also creates dependency on built-in controls; if those controls fail, problems can emerge quickly. Think of it like a thermostat that keeps a room at a steady temperature—convenient and efficient, but reliant on the thermostat working correctly.

preclinical medical

"new preclinical data related to its next-generation Emperor Total Artificial Heart"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

hemodynamic performance medical

"intended to preserve the physiological autoregulation and hemodynamic performance"

Hemodynamic performance describes how well a medical device or treatment moves and controls blood flow and pressure inside the body, like judging a pump and its pipes for steady water flow. Investors care because better hemodynamic results usually mean safer, more effective products that win regulatory approval, clinician adoption and insurance coverage, all of which affect sales, liability and long‑term value.

bridge to transplant medical

"its clinical use as a bridge to transplant for patients with advanced biventricular"

A bridge to transplant is a temporary medical treatment or device used to keep a patient stable and alive while they wait for an organ transplant, such as a heart, lung, or liver. For investors, it signals a defined market for products and services that sustain patients during the waiting period—similar to a rental car keeping someone moving until their new car arrives—affecting demand, pricing, reimbursement and regulatory risk for related companies.

biventricular heart failure medical

"bridge to transplant for patients with advanced biventricular heart failure"

Biventricular heart failure is a condition where both the right and left sides of the heart are weakened and cannot pump blood effectively, like a two-pump system losing power on both ends. It matters to investors because it increases demand for treatments, medical devices, hospital care and long-term therapies, can drive clinical-trial activity and regulatory decisions, and may affect costs and revenue for companies in cardiovascular drugs, devices and healthcare services.

electromechanical technical

"a fully implantable electromechanical artificial heart system intended to preserve"

A device, system or process that combines electrical energy and mechanical movement to perform work or control motion, like an electric motor turning gears or a sensor triggering a valve. Investors care because electromechanical products link hardware, manufacturing complexity and maintenance costs to revenue potential; reliability, supply chains and regulation can affect earnings and valuation in companies that design, make or use these components.

physiologic autoregulation medical

"designed to combine a fully implantable architecture with physiologic autoregulation"

Physiologic autoregulation is the body’s built-in ability for an organ or tissue to keep blood flow, pressure, or function steady despite changes in overall conditions, like a thermostat that adjusts heating to maintain room temperature. For investors, it matters because drugs, medical devices, or diseases that alter this self-regulation can change treatment effectiveness, safety profiles, and clinical trial results, affecting product value and market prospects.

AI-generated analysis. Not financial advice.

Poster presentation and conference exhibit will feature early preclinical data on the Company’s fully implantable, autoregulating artificial heart platform

TUCSON, Ariz., March 20, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will be presenting a poster consisting of new preclinical data related to its next-generation Emperor Total Artificial Heart at the American College of Cardiology (ACC)’s Annual Scientific Session & Expo (ACC.26) to be held in New Orleans, Louisiana from March 28 to March 30, 2026.

Abstract Poster Presentation – ACC.26

• Title: THE EMPEROR TOTAL ARTIFICIAL HEART: A FULLY IMPLANTABLE, AUTOREGULATING SOLUTION FOR ADVANCED HEART FAILURE
• Date and Time: Sunday, March 29, 2026 | 11:00 a.m. – 12:00 p.m.
• Location: Posters, Hall E
• Presenter: Duffy Elmer, Engineering Project Manager, SynCardia LLC

The poster will present early engineering and preclinical evaluation of the Emperor Total Artificial Heart, which is being developed as a fully implantable electromechanical artificial heart system intended to preserve the physiological autoregulation and hemodynamic performance of the currently approved SynCardia Total Artificial Heart while enabling fully implantable operation.

Exhibition Information

At ACC.26, SynCardia will also exhibit at booth #2554 throughout the conference.

Conference attendees are invited to visit the booth to meet with SynCardia’s engineering and clinical teams, and to learn more about the FDA approved SynCardia Total Artificial Heart, including its clinical use as a bridge to transplant for patients with advanced biventricular heart failure. Company representatives will also be available to discuss the design, development progress, and future clinical direction of the fully implantable Emperor Total Artificial Heart platform. The Company’s participation in the conference will provide an opportunity for clinicians, researchers, and industry participants to learn about SynCardia’s current clinical technology as well as its next-generation artificial heart development program.

Mr. Elmer, Engineering Project Manager, SynCardia LLC and presenter at the conference, commented, “The Emperor Total Artificial Heart represents the next evolution in total artificial heart therapy. The system is being designed to combine a fully implantable architecture with physiologic autoregulation in order to preserve the proven hemodynamic performance of the SynCardia Total Artificial Heart while enabling fully implantable long-term support. By building on the reliability and clinical experience of the SynCardia platform, the Emperor program aims to expand treatment options and improve mobility and quality of life for patients with advanced heart failure. We look forward to informing clinicians about this at the upcoming ACC conference.”

About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

What will Picard Medical (PMI) present about the Emperor Total Artificial Heart at ACC.26 on March 29, 2026?

Picard Medical will present early engineering and preclinical evaluation data for the fully implantable Emperor Total Artificial Heart. According to the company, the poster highlights an autoregulating electromechanical design intended to preserve SynCardia hemodynamics while enabling implantable operation.

Where and when is the Emperor Total Artificial Heart poster presentation at ACC.26 for PMI?

The poster presentation is on Sunday, March 29, 2026 from 11:00 a.m. to 12:00 p.m. at Posters, Hall E. According to the company, Duffy Elmer of SynCardia will present the abstract during that session.

Can investors or clinicians meet SynCardia teams from Picard Medical (PMI) at ACC.26?

Yes. SynCardia will staff exhibit booth #2554 throughout ACC.26 to meet attendees and discuss current clinical use and development progress. According to the company, engineering and clinical team members will be available at the booth.

What is the intended purpose of the Emperor Total Artificial Heart announced by PMI at ACC.26?

The Emperor program is being developed as a fully implantable, autoregulating total artificial heart system for advanced heart failure. According to the company, it aims to preserve proven hemodynamic performance while enabling long‑term implantable support and improved mobility.

Who is presenting the Emperor Total Artificial Heart poster for Picard Medical (PMI) at ACC.26?

The poster will be presented by Duffy Elmer, Engineering Project Manager at SynCardia. According to the company, Mr. Elmer will cover early engineering and preclinical evaluation findings for the Emperor platform.

Will the ACC.26 presentation discuss clinical use of the approved SynCardia Total Artificial Heart alongside the Emperor program?

Yes. SynCardia will discuss the FDA‑approved SynCardia Total Artificial Heart and the Emperor development program at the conference. According to the company, sessions and the exhibit will cover clinical use as a bridge to transplant and program direction.